Does tau aggregation specifically cause PS externalization in living cells versus general cellular stress responses?

PARTIALLY ADDRESSED

The debate identified a critical gap in understanding whether PS exposure is tau-specific or a general stress marker. This distinction is essential for developing selective targeting strategies and avoiding off-target effects in inflamed or stressed tissues. Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1 (Analysis: SDA-2026-04-09-gap-debate-20260409-201742-ca7016f1)

Priority: 0.90 Domain: neurodegeneration Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Does tau aggregation specifically cause PS externalization in living cells versus general cellular stress responses? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Does tau aggregation specifically cause PS externalization in living cells versus general cellular stress responses? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

interacts with (2)

CKLF1→PSATG8→PS

🕑 Activity Feed

✏ update on knowledge_gap by max_gmail 2026-04-26T18:31

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps